Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:00:56.138Z.
Calculation as of: 2026-10-06T20:00:56.138Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 026981202cadb8e73b6cbd63f18abfa8ffa74fea80ac6bbb32512047e0825b9f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$2.16B
Price/OCF Ratio
N/A
TTM Avg
35.55
3Y Avg
17.39
5Y Avg
17.83
Market Cap
$2.14B
Price/OCF Ratio
N/A
TTM Avg
151.58
3Y Avg
151.58
5Y Avg
151.58
Market Cap
$2.11B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.11B
Price/OCF Ratio
13.01
TTM Avg
16.43
3Y Avg
16.61
5Y Avg
17.87
Market Cap
$2.28B
Price/OCF Ratio
6.42
TTM Avg
6.21
3Y Avg
8.19
5Y Avg
14.19
Market Cap
$2.30B
Price/OCF Ratio
29.12
TTM Avg
83.65
3Y Avg
83.65
5Y Avg
83.65
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.24B | N/A | N/A | N/A | N/A |
| Pharvaris N.V. (PHVS)vs › | $2.17B | N/A | N/A | N/A | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.16B | N/A | 35.55 | 17.39 | 17.83 |
| GeneDx Holdings Corp. (WGS)vs › | $2.14B | N/A | 151.58 | 151.58 | 151.58 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 13.01 | 16.43 | 16.61 | 17.87 |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 6.42 | 6.21 | 8.19 | 14.19 |
| Vera Therapeutics, Inc. (VERA)vs › | $2.10B | N/A | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.30B | 29.12 | 83.65 | 83.65 | 83.65 |
| Alvotech (ALVO)vs › | $2.08B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
